FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 07/2024”.
The Monitor is a monthly published overview of venture capital trends in the European Healthcare & Life Sciences sector.
As of the end of July 2025 we identified the following current VC trends in Europe:
- Total Healthcare & Life Sciences funding reached EUR 6,654m (+18% vs. 2024)
- Biotech/Pharma received 41% of the total investment volume (EUR 2,704m) with oncology being the leading indication (23% of BioTech)
- In July, Nuclidium (Switzerland) secured the highest transaction volume with EUR 84m, followed by Artios (Great Britain) with EUR 70m and Ultromics (Great Britain) with EUR 50m
- GV (United States) is the most active investor (by deal volume in 2025), followed by Alphabet (United States) and Thrive Capital (United States)
To access the full report, please click here.
By Mathias Klozenbücher and Johannes Link
#FCF #Healthcare #Life #Sciences #Venture #Capital #Monitor #Europe #published
